Clinical outcome of elderly patients with metastatic colorectal cancer treated with FOLFOXIRI versus FOLFIRI: Subgroup analysis of a randomized phase III trial from the Hellenic Oncology Research Group (HORG)

Critical Reviews in Oncology/Hematology

Volumn 76, Issue 1, 2010, Pages 61-70

  Vamvakas, L ^a   Athanasiadis, A ^a   Karampeazis, A ^a   Kakolyris, S ^a   Polyzos, A ^a   Kouroussis, C ^a   Ziras, N ^a   Kalbakis, K ^a   Georgoulias, V ^a   Souglakos, J ^a  

^a Hellenic Oncology Research Group HORG   (Greece)

Author keywords

CRC; Elderly patients; FOLFIRI; FOLFOXIRI; Phase III study

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ALOPECIA; ANEMIA; BLOOD TOXICITY; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; ELDERLY CARE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERCEPTION DISORDER; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SKIN TOXICITY; THERAPY DELAY; THROMBOCYTOPENIA; VOMITING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; TREATMENT OUTCOME;

EID: 77956613335     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2009.08.003     Document Type: Review

References (28)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 2008, 58:71-96.
2. Edwards B.K., Brown M.L., Wingo P.A., et al. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 2005, 97:1407-1427.
3. European Commission DG health and consumer protection 2007, Europa Public Health.
4. Sargent D.J., Goldberg R.M., Jacobson S.D., et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001, 345:1091-1097.
5. Mattioli R., Massacesi C., Recchia F., et al. High activity and reduced neurotoxicity of bi-fractionated oxaliplatin plus 5-fluorouracil/leucovorin for elderly patients with advanced colorectal cancer. Ann Oncol 2005, 16:1147-1151.
6. Sastre J., Marcuello E., Masutti B., et al. Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish cooperative group for the treatment of digestive tumors study. J Clin Oncol 2005, 23:3545-3551.
7. Souglakos J., Pallis A., Kakolyris S., et al. Combination of irinotecan (CPT-11) plus 5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: a phase II trial. Oncology 2005, 69:384-390.
8. Goldberg R.M., Tabah-Fisch I., Bleiberg H., et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 2006, 24:4085-4091.
9. Neugut A.I., Fleischauer A.T., Sundararajan V., et al. Use of adjuvant chemotherapy and radiation therapy for rectal cancer among the elderly: a population-based study. J Clin Oncol 2002, 20:2643-2650.
10. Hutchins L.F., Unger J.M., Crowley J.J., Coltman C.A., Albain K.S. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999, 341:2061-2067.
11. Monfardini S., Sorio R., Boes G.H., Kaye S., Serraino D. Entry and evaluation of elderly patients in European organization for research and treatment of cancer (EORTC) new-drug-development studies. Cancer 1995, 76:333-338.
12. Souglakos J., Androulakis N., Syrigos K., et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer 2006, 94:798-805.
13. Wadler S., Benson A.B., Engelking C., et al. Recommended guidelines for the treatment of chemotherapy-induced diarrhea. J Clin Oncol 1998, 16:3169-3178.
14. Caussanel J.P., Levi F., Brienza S., et al. Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J Natl Cancer Inst 1990, 82:1046-1050.
15. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
16. Kohne C.H., Cunningham D., Di C.F., et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 2002, 13:308-317.
17. Feliu J., Salud A., Escudero P., et al. XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. Br J Cancer 2006, 94:969-975.
18. Sastre J., Aranda E., Massuti B., et al. Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: comparative outcomes from the 03-TTD-01 phase III study. Crit Rev Oncol Hematol 2008.
19. Folprecht G., Rougier P., Saltz L., et al. Irinotecan in first line therapy of elderly and non-elderly patients with metastatic colorectal cancer: meta-analysis of four trials investigating 5-FU and irinotecan. J Clin Oncol 2006, 24(June (18s)). [Abstract].
20. Katz S., Ford A.B., Moskowitz R.W., Jackson B.A., Jaffe M.W. Studies of illness in the aged. The index of: a standardized measure of biological and psychosocial function. JAMA 1963, 185:914-919.
21. Lawton M.P. Scales to measure competence in everyday activities. Psychopharmacol Bull 1988, 24:609-614.
22. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987, 40:373-383.
23. Neugut A.I., Matasar M., Wang X., et al. Duration of adjuvant chemotherapy for colon cancer and survival among the elderly. J Clin Oncol 2006, 24:2368-2375.
24. Townsley C., Pond G.R., Peloza B., et al. Analysis of treatment practices for elderly cancer patients in Ontario, Canada. J Clin Oncol 2005, 23:3802-3810.
25. Townsley C.A., Selby R., Siu L.L. Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. J Clin Oncol 2005, 23:3112-3124.
26. Balducci L., Hardy C.L. High proliferation of early hemopoietic progenitors in tumor-bearing mice. Pathobiology 1992, 60:68-71.
27. Balducci L., Extermann M. Cancer chemotherapy in the older patient: what the medical oncologist needs to know. Cancer 1997, 80:1317-1322.
28. Walsh S.J., Begg C.B., Carbone P.P. Cancer chemotherapy in the elderly. Semin Oncol 1989, 16:66-75.